Yahoo Finance

We also strategically divested our Los Angeles, California, property, which was leased until the closing with a combined consideration exceeding our carrying value of the property. As you may recall, that property was never fully built out for cannabis operations. Ben and Catherine will discuss this progress in more detail. The company notched another solid quarter in Q1, generating $2.21 in AFFO per share and further enhancing the company's liquidity position in the first four months of the year, with the upsizing of the revolving credit facility from $30 million to $50 million. While AFFO per share was down modestly quarter to quarter, we note that rents for the new leases we executed in late 2023 and year to date are not expected to commence for some months to come as new tenants need the time to obtain the requisite approvals to operate and transition into these properties in addition to certain pre-leased properties under development where construction needs to be completed.

As we have reiterated in the past, we are really pleased with our capital position, especially in light of the macroeconomic environment impacting real estate companies and the cannabis industry as a general matter. Our total available liquidity exceeded $200 million as of the quarter end and fully funds any remaining development commitments we have, along with providing ample dry powder for additional strategic investments. As Ben will share in more detail, we are evaluating a number of promising new investments in several state markets. Additionally, we have one of the lowest levered balance sheets in the REIT industry at 11% debt to total gross assets, no variable-rate debt, no debt maturities until May 2026. David will provide more detail as well as our financial results for the quarter and capital position.

From a regulatory perspective, all eyes continue to be focused on potential rescheduling of cannabis from schedule one to schedule three under the Controlled Substances Act, with the recent media reports indicating that the DEA is expected to agree with the HHS recommendation on this matter. Paul will discuss our thoughts in more detail on this rescheduling process pending federal legislation and state-level dynamics that we are seeing. I will now turn the call over to Paul to discuss market dynamics and regulatory developments. Paul?

Paul Smithers: Thanks, Alan. I would like to start with some general macroeconomic observations from our perspective that are impacting the regulated cannabis industry. 2023 was another year of strong growth in terms of overall unit volume for regulated cannabis sales across the United States. However, overall regulated cannabis sales growth from a dollars perspective was more subdued, given the price compression that continued through the year in many states. Although some of that price compression was driven by oversupply of regulated products in a particular market, we see much of that compression continuing to come from the illicit market. In particular, illicit grows in California to both compete within the state and have products that are transported across the country.

All that said, the outlook for overall growth of the regulated cannabis industry remains robust, with MJ Business' most recent factbook posted late April projecting overall US regulated sales to grow from $32 billion in 2024 to $58 billion by 2030. At the same time, we are seeing some relief on those pricing pressures, which gives us more optimism for 2024 and beyond as operators focus on the strength of their brands, driven in large part by the quality and consistency of their products. We also believe that the push by many of the multi-state operators to become more efficient and cost conscious in this environment should bode well for their future financial results. From a state market perspective, we continue to see divergence in performance and dynamics, with new markets experiencing high growth while some mature markets become increasingly competitive, especially after the aforementioned extended period of price compression and the challenges in competing with the illicit markets.

For example, as we noted on our last call, 2023 saw strong rollouts for adult-use sales in Missouri and Maryland, both of which also benefited from cross-border purchasing by residents in neighboring states with either medical-use-only program or no program at all. Ohio, which legalized adult use in November, is expected to commence sales this year and earlier than originally anticipated perhaps in June. While Ohio is expected to be one of the fastest growing markets in the near future and follows on the heels of very successful adult-use introductions in Missouri and Maryland, New York's adult-use program, which was introduced more than a year ago in December of 2022, has struggled. With total illicit and legal demand estimated in excess of $5 billion, New York's regulated sales in 2023 came in at well below $1 billion for the year.

However, there have been certain recent developments that make us significantly more optimistic on the prospects for New York market, including the ramping up of licensing for retail stores, stronger enforcement against illicit operations, and regulatory authorities allowing income at medical use operators to begin wholesaling. I would also like to touch on two other states that are in the running for adoption of adult-use programs in the near term, Florida and Pennsylvania. In Florida, earlier this month, the Florida Supreme Court cleared the way for a legalization initiative on the November ballot. The threshold for approval of the measure was 60%, a relatively high bar, although I would note that Florida's medical-use program passed with 72% support.

While polling has been both above and below that threshold, we will be closely following the progress there, noting that at past, Florida legalization is projected to provide the largest incremental revenue and profit opportunity for MSOs compared to any prior state conversion. In Pennsylvania, adult-use cannabis legislation has bipartisan support and is also supported by the Pennsylvania governor, having been noted as a priority in the governor's February 2024 budget address. We are hopeful that action will be taken in the coming months, also given the fact that Pennsylvania is largely surrounded by adult-use states at this point, with West Virginia as the exception. Federal legislation. From the federal perspective, we are, of course, pleased to hear, per the recent media reports, that the DEA is expected to take up the prior recommendation from HHS to reschedule cannabis from schedule one to schedule three.

As we noted previously, the most important impact of that reclassification is expected to be the elimination of the 280E tax treatment with an immediate significant boost to operator financials across the board. President Biden has made this an important issue for his administration heading into the election, and he was the first President in the United States to address cannabis reform in his state of the union address. So we believe there is significant momentum on this issue. That said, the DEA's proposed rule, when issued, will be followed by a public comment period before it issues a final rule. In that timeline, election timing and any corresponding potential administration change may also come into play. Legislatively, we also continue to track that proposed safer banking legislation which could allow, among other things, expanded lending opportunities for operators.

Though a version of this bill has passed the House seven times and has been around for the better part of a decade, recent commentary makes us think there's some potential for movement here, including commentary from Senate Majority Leader, Chuck Schumer, that the Senate is working very hard to enact this bill later this year. Treasury Secretary, Janet Yellen, also recently commented in a House committee hearing on the importance of passing reform legislation to address the banking issues presented by the current regulatory structure, which we think also may some sway in stressing the importance of resolving these issues. I'd like to now turn the call over to Ben to discuss our portfolio and leasing activity to start the year. Ben?

Ben Regin: Thanks, Paul. For my prepared remarks, I plan to highlight our continued leasing progress for our vacant and underdevelopment assets. Year to date, we've made substantial progress on this front, executing four new leases covering $69 million of invested capital in California and Michigan. California, we've executed new leases for our 19th Avenue and McLane Street properties in Palm Springs with Gold Flora, an existing tenant of ours and a leading vertically integrated operator in California. And in Michigan, as we noted last quarter, we executed an LOI for our Harvest Park facility prior to the move-out of the former tenant and, earlier this quarter, executed a lease with Lume Cannabis Company, one of the largest operators in the Michigan market.

We also signed a lease in January for one of our three small retail vacancies in the state. We were very pleased with the demand we saw for these assets, the speed at which we executed new leases, and the relatively minimal amount of incremental capital required for re-tenanting. We believe our ongoing execution on our leasing initiatives supports our underlying thesis regarding the high-quality, purpose-built, mission-critical nature of our real estate portfolio. Moving on to our development portfolio. As noted on previous calls, we continue to explore potential development options for our San Bernardino property, focusing on self storage. And we'll continue to provide updates on progress on future calls. For our land site in San Marcos, Texas, we executed an LOI for a short-term lease with one of our existing tenant partners in anticipation of potential new licenses being issued.

As you may know, Texas currently has a limited medical-use program, with only three licenses issued to date. While we remain optimistic that Texas will eventually adopt a more open approach to regulated cannabis activities and issue new licenses in that process, it remains uncertain. At our Pittsburgh, Pennsylvania, asset, we continue to explore leasing options for the property and are closely watching developments as it relates to potential adult-use legislation, as Paul alluded to previously. Regarding new investment activity, in the first four months of 2024, we executed three lease amendments to fund additional improvements at properties totaling $22.1 million, including $16 million for PharmaCann in New York, where PharmaCann is focused on expanding production capacity after being awarded an adult-use production license late last year.

In Ohio, we provided an additional $4.5 million improvement allowance to Battle Green to complete construction and expand their production capacity as Ohio gets set to roll out its adult-use program later this year. We also provided an additional $1.6 million to 4Front Ventures to round out development of 4Front's, 250,000-square-foot production facility in Illinois. Battle Green in Ohio and 4Front in Illinois both recently received their temporary certificates of occupancy, as Cat will touch on, with operations expected to commence in the near term. Finally, earlier this week, we closed on the disposition of our property in Los Angeles, which was leased up until the sale. We sold the property for $9.1 million and received a lease termination fee from the tenant of $3.9 million in addition to reimbursement of our closing costs in connection with the sale, with the total consideration exceeding the net carrying value of the property on our books.

This property was never fully built out for cannabis use, and we expect the sale to free up additional capital to recycle into other opportunities that we believe will provide superior risk-adjusted returns. In addition to our leasing activity, which has been off to a strong start in 2024, we continue to track strong active pipeline where we are seeing a notable uptick in activity on the heels of some of the market and industry developments that Paul described. We are seeing demand for our capital across markets from those with near-term adult-use potential, such as Florida and Pennsylvania, to more established markets, such as Maryland and Arizona. We are actively evaluating opportunities in these and other markets and look forward to executing on new investment opportunities on a very selective disciplined basis.

With that, I'll turn it over to Catherine. Catherine?.

Catherine Hastings: Thanks, Ben. As Ben noted, we've made a lot of progress over the last few months on closing out or nearing completion on several of our tenants' major development projects. So far, in 2024, we completed construction on three leased projects totaling $200 million of invested and committed capital: Vireo's 325,000-square-foot expansion in New York, 4Front's 250,000-square-foot ground-up development in Illinois, and Battle Green's 157,000-square-foot ground-up development in Ohio. We further expect to substantially complete the 23,000-square-foot Perez Road project in California shortly, which is pre-leased, and the 104,000 square foot cultivation component of our Summit building in Michigan in the summer. As you may recall, the 97,000-square-foot processing section of that building is accrued for operations now, and the entire project is leased.

In light of the challenges presented over the past few years with real estate development projects nationwide, we are very pleased to get these projects to the finish line and allow our operators to start generating revenues from these state-of-the-art facilities. Remember that under our lease structure, these tenants began paying rent during construction, which we recorded in our revenues. But this is an important milestone for our tenants to ramp operations and generate cash flows in the facilities. Regarding our portfolio as of March 31 and pro forma for development properties placed into service subsequent to quarter end, we owned 108 properties across 19 states, comprising 8.9 million rentable square feet, including 647,000 square feet of development or redevelopments.

Of these 108 properties, 103 properties are included in our operating portfolio, which was 95.2% leased at quarter end with a weighted average remaining lease term of approximately 14.8 years. Of the five properties under development -- redevelopment, three were pre-leased at quarter end. Our portfolio continues to be well diversified, with no one tenant representing more than 17% of our annualized base rent and no state representing more than 15% of our annualized base rent. We have relationships with some of the largest and most experienced operators in the industry, with our leased operating portfolio comprised of 90% multi-state operators and 60% leased to public company tenants. The total amount of capital invested and committed across our operating portfolio equates to $277 per square foot, which we believe remains significantly below replacement cost.

And with that, I'll turn it over to David. David?

David Smith: Thank you, Catherine. For the first quarter, we generated total revenues of $75.5 million, a 1% decrease from Q1 of last year. Decrease was primarily driven by properties which were leased for all or part of the three months ended March 31, 2023, and properties which were not leased or were re-leased, but rent had not yet commenced, during the three months ended March 31, 2024. As we noted in our earnings release issued yesterday, total revenues for Q1 also do not include $1.5 million in rent received during the quarter, but not recognized in total revenues, due to a reclassification of two leases and sales type leases starting January 1, 2024, as a result of lease term extensions that were executed for both leases.

The modest decline in rental revenues was partially offset by activity in prior periods for the acquisition and leasing of new properties, additional funding and building improvements provided to tenants at certain properties that resulted in base rent increases, and contractual rental escalations. It's also noteworthy that no security deposits were applied for payment of rent during the three months ended March 31, 2024, while a total of $4.2 million of secured deposits were applied for payment of rent for Q1 in 2023. Revenues for the quarter were also down sequentially versus Q4 of last year, primarily related to a Q4 payment of $1.7 million received from a former tenant at one of our properties in Pennsylvania as part of a judgment in our favor for unpaid rent and a previously disclosed temporary reduction in base rent for 4Front at the Illinois property starting in January 2024, which was under development and had experienced significant delays in construction, primarily relating to bringing power to the property.

For the three months ended March 31, 2024, we recorded net income attributable to common stockholders of $39.1 million, or $1.36 per share. Adjusted funds from operations for the first quarter was $63 million, or $2.21 per share, a decrease of 2% compared to the first quarter of 2023, driven primarily by the same factors that drove the 1% decrease in revenues period to period. AFFO was also down sequentially from Q4, again primarily driven by the $0.06 attributable to the $1.7 million judgment paid to IIP in Q4. Looking ahead, I would note that while we expect the leasing activity Ben discussed to contribute meaningfully to our long-term rental revenues, the timeline to rent stabilization may differ between the properties as there are state and local approvals needed for these transitions, additional regulatory requirements to be completed at certain assets, and some level of rent abatements negotiated to allow for a ramping of our new tenant's operations.

That being said, we are very pleased with our substantial activity on the re-leasing front, as Ben discussed in detail. On April 15 , we paid a quarterly dividend of $1.82 per share to common stockholders of record as of March 28. As Alan noted, our dividend remain covered by our AFFO during the quarter, with a payout ratio of 82%, which is in line with the Board's targeted payout ratio of 75% to 85% of AFFO. Turning to the balance sheet. At quarter end, we had approximately $2.6 billion of total gross assets and $300 million in fixed rate debt, consisting solely of $300 million in unsecured bonds not maturing until May 2026. We continue to maintain credit metrics that are among the best in the entire publicly traded REIT industry with a debt-to-gross-assets ratio of 11% and a debt service coverage ratio in excess of 16 times.

On the liquidity front, we ended the first quarter with over $200 million of total liquidity comprised of our cash, short-term investments, and availability under our revolving credit facility. We closed on this credit facility last October [Technical Difficulty] at that time was a $30 million three-year facility, subsequently upsized the facility to $45 million in February, and expect to increase the total capacity to $50 million by the end of this month. Our revolver remains undrawn as of today. We are also continuing to source new banking relationships to provide additional capital for the company. And with over 800 financial institutions providing services to the cannabis industry, along with recent reports of one of the top 20 largest banks in the US entering the industry, we remain encouraged in our prospects to continue to expand our banking relationships.

We are well positioned for growth as we continue to maintain a conservative and low-leverage balance sheet, generate positive free cash flow, and have continued to enhance our liquidity position through the closing of this new credit facility in Q4 and upsizing that facility in the first part of 2024. Finally, as a result of the investment activity that Ben mentioned, we opportunistically tapped our ATM program by issuing 123,000 shares of common stock for $11.8 million in net proceeds to further bolster our strong liquidity position and invest accretively into the opportunities that Ben discussed in his remarks. With that, I will turn it back to Alan. Alan?

Brian Wolfe: Thanks, David. I'd like to note the following in closing. We, as a company, are certainly not immune to the macroeconomic factors that have impacted the broader economy and the regulated cannabis industry in particular. But I am proud of our team and what our team has accomplished in continuing to execute on our plan to maximize the value of our portfolio for the benefit of our stockholders through our leasing, investment, and disposition activities and to continually evaluate capital options with the goal of maintaining a strong balance sheet and liquidity position. We believe this core focus will serve our stockholders well over the long term. With that, I'd like to open it up to questions. Operator, could you please open the call up for questions?

See also

10 Best Dividend Leaders to Buy According to Analysts and

11 Best Low Price Pharma Stocks To Invest In.

To continue reading the Q&A session, please click here.